CytomX Bounces Back From Trial Setback With Regeneron Bispecific Antibody Partnership

Gets $30m Upfront

 
• By Ayisha Sharma

The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.    

Yellow ball on white background, bounce motion with white powder
CytomX's Share Price Increased By More than 20% In Response To The News • Source: Shutterstock

More from Deals

More from Business